ANARI-AI
20.4.2021 14:01:13 CEST | Business Wire | Press release
Anari AI , an AI chip factory in the cloud, today announced it has raised $2 million in seed funding led by Earlybird , with participation from Acequia Capital , Serbian Entrepreneurs , and Eric Ries , author and founder of The Lean Startup . The new funding will be used to continue developing the platform and bring it to market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005700/en/
Anari’s platform makes it possible to design personalized AI chips in the cloud with just one click. With this approach, companies are able to build and deploy AI solutions in weeks instead of 12-18 months, and at a fraction of the cost of traditional hardware development.
“AI continues to be growing in size and complexity, and this rate of growth is outpacing standard CPU and GPU performance gains,” said Roland Manger , co-founder and Partner at Earlybird. “Dedicated designs or flexible architectures are expensive, time-consuming and require hardware skills (in short: take lots of effort). Anari is a game changer in two ways: it removes the trade-off between performance and effort, and it makes AI-problem-specific chip solutions available instantaneously in the cloud. I am excited about this huge potential.”
The platform is built on a unique Python-based programming framework—developed by Anari for chip design—that opens up new possibilities for hardware engineers and turns software engineers into hardware designers. The first configurable AI cloud chip from Anari is Thor X, which delivers 100x more efficient processing of 3D Point Cloud/Graph data structures compared to a high-end GPU.
Anari’s team consists of Ph.D. researchers, machine learning experts, and senior software engineers. The team is led by Jovan Stojanovic (co-founder and CEO), Stefan Sredojevic (co-founder and COO), and Bogdan Vukobratovic (co-founder and Head of R&D). Jovan is the founder of the Wonderland AI community that includes more than 30,000 AI experts and enthusiasts from all over the world. The yearly Wonderland AI Summit gathers C-level speakers and attendees from the world’s leading AI companies like NVIDIA, Airbus, HP, IBM, Mercedes, etc.
“You no longer have to tune your model to the computing infrastructure that’s available and designed for broad and generic use cases,” said Sasha Ostojic , ex-VP at NVIDIA, ex-SVP at Cruise Automation, Advisor at Samsung Electronics and Zoox, and Operating Partner at Playground Global.“ Anari's cloud chip technology is the future of cloud computing.”
Roland Manger and Sasha Ostojic will be joining Anari's Board of Directors. Advisors to the company include Christoph Auer-Welsbach (former Partner at IBM Ventures, Founder of CITY AI, and CEO of Kaizo) and Dejan Markovic (co-founder of Flex Logix and Professor at UCLA).
“With AI model complexity doubling every three and a half months, the current way of building the AI infrastructure is not sustainable,” said Jovan Stojanovic, co-founder and CEO of Anari AI. “We believe that every company deserves to have a personalized chip for their AI in just one click. We’re supporting the rapid progress of AI in ways that haven’t been possible until now. With experienced investors like Earlybird on our side, we’re ready to rebuild the AI hardware industry from scratch.”
About Anari AI
Anari AI is rebuilding the AI hardware industry from scratch by delivering a new way of designing and using AI chips through programming in the cloud. The Anari platform for cloud chips can be used by companies across industries such as gaming, automotive and biotechnology to personalize their AI infrastructure with just one click. The company is based in Serbia and has an office in San Francisco. The global team includes advisors with experience from NVIDIA, CERN, IBM, UC Berkeley, and UCLA.
For more information, visit www.anari.ai .
About Earlybird VC
Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company. Amongst the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support as well as access to an international network and capital markets.
Earlybird Venture Capital has grown to three autonomous, dedicated and specialized teams, focusing on digital technologies in Eastern and Western Europe as well as health technologies. Among them, the Digital East Fund is focused on early stage ICT investment opportunities in Eastern Europe and Turkey, being the leading tech VC in this region. With EUR 1.5 billion under management, seven IPOs and 30 trade sales, Earlybird is one of the most successful venture capital firms in Europe. Discover more at www.earlybird.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005700/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release
With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release
Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom